Drug intelligence / Profile preview

VNS-002

Development stage: Preclinical
Lead developer: Vianautis
Modality: Gene Therapies, Nanoparticles → Drug Delivery Systems, RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Inhalation

Overview

VNS-002 is a preclinical genetic-medicine program from ViaNautis Bio that uses the company’s polyNaut platform to enable targeted delivery of genetic cargos to the conducting airways for the treatment of cystic fibrosis. The program is supported by the Cystic Fibrosis Foundation and focuses on identifying optimal formulation candidates for lung airway delivery. While the exact cargo has not been publicly specified, ViaNautis’ platform is designed to deliver plasmid DNA, mRNA, siRNA, or antisense oligonucleotides using polymer-based nanoparticles engineered for barrier penetration and cell-specific targeting.[3][5][7][1]

Other names: VNS002VNS-002VNS 002

Beyond the preview

Go deeper on VNS-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VNS-002.

Explore the full profile